Der Internist

, Volume 50, Issue 9, pp 1111–1126

Interstitielle Nephritis

  • J. Halbritter
  • C. Mayer
  • F.M. Rasche
  • K. Amann
  • T.H. Lindner
CME - Weiterbildung - Zertifizierte Fortbildung

Zusammenfassung

Die interstitielle Nephritis beschreibt entzündliche Krankheitsentitäten, die im Wesentlichen im tubulointerstitiellen Raum stattfinden. Auslöser für interstitielle Nephritiden sind Medikamente (z. B. Antibiotika, nichtsteroidale Antirheumatika, Protonenpumpenhemmer), Infektionen und Systemerkrankungen. Die Klinik reicht vom asymptomatischen Verlauf über Flankenschmerzen bis zum akuten Nierenversagen. Häufig kommt es zu charakteristischen, detektierbaren tubulären Partialfunktionsstörungen: tubuläre Proteinurie (α1-Mikroglobulin), Hyperphosphaturie mit Hypophosphatämie, Aminoazidurie, verminderte H+-Sekretion mit metabolischer Azidose mit inadäquat hohem Urin-pH-Wert, Glukosurie, Salzverlust. Bei der medikamentös induzierten Form ist das Weglassen des auslösenden Agens oberstes Prinzip, nach Infektionsausschluss hat sich die Gabe von Kortikosteroiden bewährt. In der Mehrzahl der Fälle mit akutem Verlauf ist mit einer günstigen Prognose zu rechnen, bei der chronischen Verlaufsform, bei der auch die Glomeruli betroffen sind, bedarf es aller supportiven Maßnahmen im Sinne der Behandlung der chronischen Niereninsuffizienz, um eine weitere Funktionsverschlechterung bis zur Entwicklung einer ESRD („end-stage renal disease“) abzuwenden.

Schlüsselwörter

Interstitielle Nephritis Tubulointerstitielle Nephritis und Uveitis (TINU) Analgetikanephropathie Balkan-Nephritis Lithium-Nephropathie 

Interstitial nephritis

Abstract

Drugs such as antibiotics, non-steroidal anti-inflammatory drugs and proton pump inhibitors, infections and systemic diseases can trigger interstitial nephritis. The clinical outcome varies from asymptomatic progression to acute kidney injury. Interstitial nephritis often leads to characteristic and detectable partial tubular disorders such as tubular proteinuria (α1-microglobulin), phosphaturia with hypophosphatemia, aminoaciduria, diminished H+ secretion with metabolic acidosis with inadequate high urinary pH, glucosuria and salt loss. The main principle of treatment is avoidance of the inducing agent. In addition corticosteroids have been proven usable after exclusion of an infection so that a good prognosis can be expected for acute nephritis in the majority of cases. In chronic forms the interstitial nephritis involves the glomeruli as well as potentially resulting in end-stage renal failure in the long run. Supportive therapies are then required in the sense of chronic renal failure in order to prevent further functional loss up to end-stage renal disease.

Keywords

Interstitial nephritis Tubulointerstitial nephritis and uveitis (TINU) Analgesic nephropathy Balkan-endemic nephropathy Lithium kidney disease  

Literatur

  1. 1.
    Baker RJ, Pusey CD (2004) The changing profile of acute tubulointerstitial nephritis. Nephrol Dial Transplant 19(1):8–11PubMedCrossRefGoogle Scholar
  2. 2.
    Michel DM, Kelly CJ (1998) Acute interstitial nephritis. J Am Soc Nephrol 9(3):506–515PubMedGoogle Scholar
  3. 3.
    Clarkson MR et al (2004) Acute interstitial nephritis: clinical features and response to corticosteroid therapy. Nephrol Dial Transplant 19(11):2778–2783PubMedCrossRefGoogle Scholar
  4. 4.
    Nolan CR 3rd, Anger MS, Kelleher SP (1986) Eosinophiluria – a new method of detection and definition of the clinical spectrum. N Engl J Med 315(24):1516–1519PubMedGoogle Scholar
  5. 5.
    Rossert J (2001) Drug-induced acute interstitial nephritis. Kidney Int 60(2):804–817PubMedCrossRefGoogle Scholar
  6. 6.
    Galpin JE et al (1978) Acute interstitial nephritis due to methicillin. Am J Med 65(5):756–765PubMedCrossRefGoogle Scholar
  7. 7.
    Nolan CM, Abernathy RS (1977) Nephropathy associated with methicillin therapy. Prevalence and determinants in patients with staphylococcal bacteremia. Arch Intern Med 137(8):997–1000PubMedCrossRefGoogle Scholar
  8. 8.
    Ra A, Tobe SW (2004) Acute interstitial nephritis due to pantoprazole. Ann Pharmacother 38(1):41–45PubMedCrossRefGoogle Scholar
  9. 9.
    Ricketson J et al (2009) Acute allergic interstitial nephritis after use of pantoprazole. CMAJ 180(5):535–538PubMedGoogle Scholar
  10. 10.
    Sierra F et al (2007) Systematic review: Proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther 26(4):545–553PubMedCrossRefGoogle Scholar
  11. 11.
    Abdul Ghani R et al (2009) Acute renal failure following the use of rosiglitazone in a chronic kidney disease patient. Singapore Med J 50(1):e32–e34Google Scholar
  12. 12.
    Gurevich F, Perazella MA (2009) Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med 122(4):322–328PubMedCrossRefGoogle Scholar
  13. 13.
    Patel H, Barr A, Jeejeebhoy KN (2009) Renal effects of long-term treatment with 5-aminosalicylic acid. Can J Gastroenterol 23(3):170–176PubMedGoogle Scholar
  14. 14.
    Bennett WM, DeBroe ME (1989) Analgesic nephropathy–a preventable renal disease. N Engl J Med 320(19):1269–1271PubMedGoogle Scholar
  15. 15.
    Pinter I et al (2004) Analgesic nephropathy in Hungary: the HANS study. Nephrol Dial Transplant 19(4):840–843PubMedCrossRefGoogle Scholar
  16. 16.
    Perneger TV, Whelton PK, Klag MJ (1994) Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. N Engl J Med 331(25):1675–1679PubMedCrossRefGoogle Scholar
  17. 17.
    Curhan GC et al (2004) Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med 164(14):1519–1524PubMedCrossRefGoogle Scholar
  18. 18.
    Boton R, Gaviria M, Batlle DC (1987) Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am J Kidney Dis 10(5):329–345PubMedGoogle Scholar
  19. 19.
    Presne C et al (2003) Lithium-induced nephropathy: Rate of progression and prognostic factors. Kidney Int 64(2):585–592PubMedCrossRefGoogle Scholar
  20. 20.
    Waller DG, Edwards JG, Papasthatis-Papayanni S (1988) A longitudinal assessment of renal function during treatment with lithium. Q J Med 68(255):553–558PubMedGoogle Scholar
  21. 21.
    Farres MTet al (2003) Chronic lithium nephropathy: MR imaging for diagnosis. Radiology 229(2):570–574PubMedCrossRefGoogle Scholar
  22. 22.
    Markowitz GS et al (2000) Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy. J Am Soc Nephrol 11(8):1439–1448PubMedGoogle Scholar
  23. 23.
    Yang CW (2007) Leptospirosis renal disease: understanding the initiation by Toll-like receptors. Kidney Int 72(8):918–925PubMedCrossRefGoogle Scholar
  24. 24.
    Muranyi W et al (2005) Hantavirus infection. J Am Soc Nephrol 16(12):3669–3679PubMedCrossRefGoogle Scholar
  25. 25.
    Poux JM et al (1992) Hypokalemic quadriplegia and respiratory arrest revealing primary Sjogren’s syndrome. Clin Nephrol 37(4):189–191PubMedGoogle Scholar
  26. 26.
    Shearn MA, Tu WH (1965) Nephrogenic diabetic insipidus and other defects of renal tubular function in sjoergren’s syndrome. Am J Med 39:312–318PubMedCrossRefGoogle Scholar
  27. 27.
    Bastani B et al (1995) Lack of H-ATPase in distal nephron causing hypokalaemic distal RTA in a patient with Sjogren’s syndrome. Nephrol Dial Transplant 10(6):908–909PubMedGoogle Scholar
  28. 28.
    Stolt A et al (2003) Seroepidemiology of the human polyomaviruses. J Gen Virol 84(Pt 6):1499–1504PubMedCrossRefGoogle Scholar
  29. 29.
    Shah KV (2000) Human polyomavirus BKV and renal disease. Nephrol Dial Transplant 15(6):754–755PubMedCrossRefGoogle Scholar
  30. 30.
    Hirsch HH et al (2002) Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 347(7):488–496PubMedCrossRefGoogle Scholar
  31. 31.
    Saad ER et al (2008) Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. Transplantation 85(6):850–854PubMedCrossRefGoogle Scholar
  32. 32.
    Kuypers DR et al (2005) Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. Am J Transplant 5(8):1997–2004PubMedCrossRefGoogle Scholar
  33. 33.
    Blanckaert K, De Vriese AS (2006) Current recommendations for diagnosis and management of polyoma BK virus nephropathy in renal transplant recipients. Nephrol Dial Transplant 21(12):3364–3367PubMedCrossRefGoogle Scholar
  34. 34.
    Asberg A et al (2007) Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 7(9):2106–2113PubMedCrossRefGoogle Scholar
  35. 35.
    Farrugia E, Schwab TR (1992) Management and prevention of cytomegalovirus infection after renal transplantation. Mayo Clin Proc 67(9):879–890PubMedGoogle Scholar
  36. 36.
    Dobrin RS, Vernier RL, Fish AL (1975) Acute eosinophilic interstitial nephritis and renal failure with bone marrow-lymph node granulomas and anterior uveitis. A new syndrome. Am J Med 59(3):325–333PubMedCrossRefGoogle Scholar
  37. 37.
    Abed L et al (2008) Presence of autoantibodies against tubular and uveal cells in a patient with tubulointerstitial nephritis and uveitis (TINU) syndrome. Nephrol Dial Transplant 23(4):1452–1455PubMedCrossRefGoogle Scholar
  38. 38.
    Sessa A et al (2000) Acute renal failure due to idiopathic tubulo-intestinal nephritis and uveitis: „TINU syndrome“. Case report and review of the literature. J Nephrol 13(5):377–380PubMedGoogle Scholar
  39. 39.
    Simon AH, Alves-Filho G, Ribeiro-Alves MA (1996) Acute tubulointerstitial nephritis and uveitis with antineutrophil cytoplasmic antibody. Am J Kidney Dis 28(1):124–127PubMedCrossRefGoogle Scholar
  40. 40.
    Djukanovic L et al (2002) Epidemiology of end-stage renal disease and current status of hemodialysis in Yugoslavia. Int J Artif Organs 25(9):852–859PubMedGoogle Scholar
  41. 41.
    Cosyns JP et al (1994) Chinese herbs nephropathy: a clue to Balkan endemic nephropathy? Kidney Int 45(6):1680–1688PubMedCrossRefGoogle Scholar
  42. 42.
    Bukvic D et al (2005) Balkan endemic nephropathy is still present in the Kolubara region, Serbia. Ren Fail 27(5):565–569PubMedCrossRefGoogle Scholar
  43. 43.
    Petronic VJ et al (1991) Balkan endemic nephropathy and papillary transitional cell tumors of the renal pelvis and ureters. Kidney Int Suppl 34:S77–S79PubMedGoogle Scholar
  44. 44.
    Stewart JH et al (2003) Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand. J Am Soc Nephrol 14(1):197–207PubMedCrossRefGoogle Scholar
  45. 45.
    Appel GB (2008) The treatment of acute interstitial nephritis: More data at last. Kidney Int 73(8):905–957PubMedCrossRefGoogle Scholar
  46. 46.
    Buysen JG et al (1990) Acute interstitial nephritis: a clinical and morphological study in 27 patients. Nephrol Dial Transplant 5(2):94–99PubMedGoogle Scholar
  47. 47.
    Gonzalez E et al (2008) Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int 73(8):940–946PubMedCrossRefGoogle Scholar
  48. 48.
    Preddie DC et al (2006) Mycophenolate mofetil for the treatment of interstitial nephritis. Clin J Am Soc Nephrol 1(4):718–722PubMedCrossRefGoogle Scholar
  49. 49.
    Mayer C et al (2008) Isolated renal relapse of sarcoidosis under low-dose glucocorticoid therapy. J Gen Intern Med 23(6):879–882PubMedCrossRefGoogle Scholar
  50. 50.
    Strutz FM (2009) EMT and proteinuria as progression factors. Kidney Int 75(5):475–481PubMedCrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag 2009

Authors and Affiliations

  • J. Halbritter
    • 1
  • C. Mayer
    • 1
  • F.M. Rasche
    • 1
  • K. Amann
    • 2
  • T.H. Lindner
    • 1
  1. 1.Medizinische Klinik und Poliklinik für Endokrinologie und Nephrologie, Department für Innere Medizin, Neurologie und DermatologieUniversitätsklinikum Leipzig, A.ö.R., LeipzigLeipzigDeutschland
  2. 2.Nephropathologische AbteilungUniversitätsklinikum ErlangenErlangenDeutschland

Personalised recommendations